Seropositive RA patients more often adhere to abatacept compared to TNF, JAK Inhibitors: Study
Among seropositive RA patients, those on abatacept were more often persistent to their index treatment and had longer time to treatment discontinuation at 1 year compared to patients on TNFi or JAKi which may be reflective of treatment efficacy. The findings suggest that the modified antibody therapy is associated with greater adherence than competitor therapies for rheumatoid arthritis.
The new data was presented at the American College of Rheumatology (ACR) 2021 Convergence.A team of Bristol Myers Squibb (BMS) investigators conducted a study to describe treatment persistence to abatacept and 2 comparison treatment groups tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi) among Medicare patients with seropositive RA.
Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept experience increased clinical efficacy compared to those treated with other biologic or targeted synthetic (b/ts) DMARDs. This biomarker-defined patient group may also demonstrate increased treatment durability. The objective of this study was to describe treatment persistence to abatacept and 2 comparison treatment groups (tumor necrosis factor inhibitors [TNFi] and Janus kinase inhibitors [JAKi]) among Medicare patients with seropositive RA.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.